Related Experiment Video
Updated: Jan 16, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
CAPTURE and PUMA as Case-Finding Tools in Patients at Risk of COPD-A Multicenter Mexican Experience
Arturo Cortes-Telles1, Ismael Juarez-de-Dios2, Esperanza Figueroa-Hurtado1
1Clinica de Enfermedades Respiratorias, Hospital Regional de Alta Especialidad de la Peninsula de Yucatan IMSS-Bienestar, Merida 97130, Mexico.
Abstract:
Background/Objectives: Chronic obstructive pulmonary disease (COPD) is a significant global challenge affecting health systems, economies, and societies. There is a need to implement case-finding strategies to identify patients at risk of COPD in routine clinical practice in low- and middle-income countries where underdiagnosis is high and access to spirometry is limited. PUMA and CAPTURE questionnaires are available for COPD screening; their comparative effectiveness has not been evaluated in Mexican patients. Methods: Multicenter, cross-sectional, case-finding study. PUMA and CAPTURE with spirometry test were used in COPD screening campaigns. Adults >40 years of age with current and former smoking, exposure to wood or charcoal, with and without chronic respiratory symptoms were eligible. COPD was confirmed by a post-bronchodilator FEV1/FVC < 0.70. Sensitivity and specificity were calculated for each questionnaire. Correlations between PUMA and CAPTURE scores and FEV1/FVC were evaluated. Propensity score matching (PSM) was performed for patients with/without COPD. Results: In total, 197 subjects were enrolled. COPD was diagnosed in 37.1% of the patients. The cut-off point for PUMA with the best sensitivity (74.0%) and specificity (51.6%) was ≥6. CAPTURE showed cut-off points of ≥3 (sensitivity 76.9%, specificity (40.9%) or ≥4 (sensitivity 61.5%, specificity 72.7%). ROC for PUMA was 0.693 (95% IC 0.618-0.768) and for CAPTURE was 0.714 (95% IC 0.570-0.857). Correlations for PUMA and CAPTURE with FEV1/FVC were -0.390 (p < 0.001) and -0.406 (p = 0.004), respectively. There were no changes in the cut-off points and correlations after the PSM for PUMA or CAPTURE to identify patients with COPD. Conclusions: In Mexican patients, both questionnaires had moderate certainty in the diagnosis of patients at risk for COPD with a spirometric obstructive pattern.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Management Using Bronchodilators and Corticosteroids
Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

